

Correction: *Effect of PIFR-based optimised inhalation therapy in patients recovering from acute exacerbation of chronic obstructive pulmonary disease: protocol of a prospective, multicentre, superiority, randomised controlled trial*

Hua J, Zhang W, Cao H, *et al.* Effect of PIFR-based optimised inhalation therapy in patients recovering from acute exacerbation of chronic obstructive pulmonary disease: protocol of a prospective, multicentre, superiority, randomised controlled trial. *BMJ Open* 2020;10:e034804. doi: 10.1136/bmjopen-2019-034804.

The authors want to alert readers to the following update in the published version.

On page 3 the line “Spiriva HandiHaler (18 µg once a day) or Spiriva Respimat (2.5 µg once a day, Boehringer Ingelheim Pharma & Co KG) will be given in combination with ICS/LABA” has been corrected to “Spiriva HandiHaler (18 µg once a day) or Spiriva Respimat (2.5 µg twice a day, Boehringer Ingelheim Pharma & Co KG) will be given in combination with ICS/LABA.”

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

BMJ Open 2020;10:e034804corr1. doi:10.1136/bmjopen-2019-034804corr1

